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Phase II Trial of Weekly Dose-Dense Paclitaxel in
Extensive-Stage Small Cell Lung Cancer
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Stephen L. Graziano, MD,* James E. Herndon, II, PhD,† Mark A. Socinski, MD,‡
Xiaofei Wang, PhD,† Dorothy Watson,† Everett Vokes, MD,§ and Mark R. Green, MD,
and for the Cancer and Leukemia Group B
Introduction: Paclitaxel is an active agent in extensive-stage (ES)
small cell lung cancer (SCLC). Nevertheless, the optimal schedule is
uncertain. A dose-dense schedule was previously evaluated in a
Cancer and Leukemia Group B study of patients with non-SCLC,
resulting in a 42% response rate and median survival of 12.3
months. Because of these promising results, this dose and schedule
of paclitaxel was evaluated in patients with ES-SCLC.
Methods: Patients were eligible for this phase II trial (Cancer and
Leukemia Group B 39901) if they had documented ES-SCLC, no
prior chemotherapy, and performance status of 0 to 2. Paclitaxel was
administered as an intravenous infusion at 150 mg/m2 over 3 hours
weekly for 6 consecutive weeks every 8 weeks.
Results: Thirty-six patients with median age of 65 were enrolled. Of
them 25 were men and 33 with a performance status 0 to 1. A
median of two 8-week cycles were delivered. The percent of patients
with grade 3/4 toxicity included neutropenia 22%, anemia 9%,
febrile neutropenia 6%, fatigue 20%, sensory neuropathy 26%,
motor neuropathy 11%, and dyspnea 17%. There were two treat-
ment-related deaths, both from pneumonitis. The overall response
rate was 33% (3% complete response and 30% partial response).
Median progression-free and overall survivals were 3.7 and 9.2
months, respectively. One-year progression-free and overall surviv-
als were 17% and 36%, respectively.
Conclusions: For patients with ES-SCLC, dose-dense weekly pac-
litaxel was associated with fairly mild hematologic toxicity. Never-
theless, nonhematologic toxicities, including neuropathy, fatigue,
and dyspnea required frequent dose delays and reductions. The
overall response rate is disappointing and much lower than that seen
with standard platinum-based combinations. Paclitaxel in this dose
and schedule should not be used as front-line therapy for patients
with ES-SCLC.
Key Words: Small cell lung cancer, Extensive stage, Paclitaxel,
Chemotherapy.
(J Thorac Oncol. 2008;3: 158–162)
Lung cancer remains the leading cause of cancer-relatedmortality in the United States.1 Of the expected 174,000
new cases reported in 2006, approximately 13% will be small
cell lung cancer (SCLC).2 Although advances in the treatment
of limited-stage SCLC, such as the addition of thoracic
radiation therapy3 and the use of prophylactic cranial irradi-
ation,4 have improved survival, advances in extensive-stage
(ES) SCLC have been less apparent. Etoposide in combina-
tion with cisplatin or carboplatin has been the most often used
regimen for the past two decades. Various strategies such as
maintenance topotecan5 or oral etoposide6 have not made
meaningful improvements in the overall survival of ES-
SCLC patients. There has been interest in substitution of
irinotecan for etoposide in combination with cisplatin as
demonstrated in Japan Clinical Oncology Group 9511 trial.7
Nevertheless, this experience has not yet been confirmed in
the United States. One recently reported trial showed no
difference in survival outcomes,8 and a Southwest Oncology
Group phase III trial, similar in design to Japan Clinical
Oncology Group 9511, has recently completed accrual and
has not yet been reported. Certainly, new and novel strategies
are needed in this setting.
Paclitaxel is an active agent in SCLC with initial phase
II trials showing response rates of 34 to 53% as a single agent
in previously untreated patients. The North Central Cancer
Treatment Group gave paclitaxel 250 mg/m2 over 24 hours
with granulocyte colony stimulating factor (G-CSF) every 3
weeks and reported a response rate of 53% and a median
survival of 9.1 months.9 Using a similar regimen, the Eastern
Cooperative Oncology Group reported a 34% response rate
and a median survival of 9.9 months.10 In previously treated
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patients, Smit et al. reported a response rate of 29%. All
patients had refractory disease (relapse within 3 months of
cytotoxic therapy), and median survival was only 3.3
months.11 In another small study of second-line chemo-
therapy of patients who received weekly paclitaxel 80
mg/m2 for 6 weeks in an 8-week cycle, 33% achieved a
partial remission.12
The optimal schedule of paclitaxel has not been de-
fined. Weekly schedules have been tested in a number of
disease sites, including ovary, breast, and non-SCLC
(NSCLC), with similar activity but perhaps less toxicity
compared with more-conventional every 3-week strategy.13–15
Akerley et al. have previously explored a dose-dense sched-
ule of single-agent paclitaxel in advanced NSCLC.16,17 In the
Cancer and Leukemia Group B (CALGB) phase II trial, 38
patients received a dose of paclitaxel of 150 mg/m2/wk for 6
consecutive weeks every 8 weeks. The overall response rate
was 42% with a median survival time and 1- and 2-year
survival rates of 12.3 months, and 52% and 26%, respec-
tively. The primary toxicities of this strategy were neutrope-
nia, neuropathy, and hyperglycemia. Given this level of
activity in advanced NSCLC and the need for novel strategies
in ES-SCLC, the CALGB evaluated weekly dose-dense pac-
litaxel in ES-SCLC.
PATIENTS AND METHODS
Patients entered onto this phase II trial (CALGB 39901)
were required to have ES-SCLC documented histologically
or cytologically. ES was defined as those patients with ex-
trathoracic metastatic disease, malignant pleural effusion, or
contralateral supraclavicular or hilar adenopathy (precluding
definitive radiation therapy). No prior chemotherapy for
SCLC was allowed and patients had to be at least 2 weeks
from any prior radiation therapy. A performance status of 0 to
2 was required, and patients had to be at least 18 years old.
Patients were also required to have an absolute neutrophil
count (ANC) of 1500/l, platelet count of 100,000/l,
serum glutamic oxaloacetic transaminase (SGOT)  2 
upper limits of normal (ULN), and bilirubin 1.5 mg/dl.
Measurable disease was required. Before entry onto this trial,
patients were required to have a chest radiograph, computed
tomography scan, or magnetic resonance imaging of the chest
and abdomen, bone scan, and computed tomography or mag-
netic resonance imaging of the brain.
Paclitaxel was administered as an intravenous (IV)
infusion at 150 mg/m2 over 3 hours weekly for 6 consecutive
weeks every 8 weeks. Before receiving paclitaxel, patients
received standard prophylactic medications, including dexa-
methasone 20 mg orally 12 and 6 hours before or 20 mg IV
30 minutes before paclitaxel, diphenhydramine 50 g IV 30
minutes before paclitaxel and cimetidine (300 mg IV), rani-
tidine (50 mg IV) or famotidine (20 mg IV) 30 minutes before
paclitaxel. A total of four 8-week cycles were planned,
assuming the patient had acceptable tolerance of the treat-
ment and no evidence of disease progression.
A complete blood count and toxicity assessment was
performed weekly whereas liver enzymes were assessed ev-
ery 8 weeks. The weekly dose of paclitaxel was omitted if the
ANC was 1000/l or the platelets were 75,000/l. If the
ANC was 1000 to 1499/l or the platelets were 75,000 to
99,000/l, the paclitaxel dose was reduced by 50%. A 50%
dose reduction was also required for grade 2 or higher
neuropathy after the first cycle. Paclitaxel was held for any
grade 3 or higher neurotoxicity during any cycle. If recovery
to grade 2 neurotoxicity occurred, paclitaxel could be
reinstituted at a 50% dose reduction for all subsequent cycles.
Paclitaxel was also dose reduced by 50% for elevations in the
SGOT of 2 to 5 ULN and omitted for5 ULN in SGOT
or elevations in the bilirubin to 1.4 mg/dl. Doses were also
omitted for any other grade 3/4 nonhematologic toxicities.
Patients were to receive full supportive care, including
transfusions, erythropoietin, antibiotics, and antiemetics, as ap-
propriate. The routine use of myeloid growth factors (G-CSF
and granulocyte macrophage colony stimulating factor) was
discouraged. They were not used to avoid dose reductions,
delays, or to allow for dose escalation and could not be used
prophylactically because of concern about myelosuppression.
For the treatment of febrile neutropenia, the use of CSFs could
be used according to American Society of Clinical Oncology
guidelines.
Response assessments were done with each cycle of
treatment (every 8 weeks), and responses were evaluated
using RECIST criteria.18 Measurable disease was required for
eligibility. Confirmation of response was to be obtained 4 to
6 weeks later.
The primary goal of the study was to evaluate the
activity of weekly dose-dense paclitaxel in ES-SCLC. A
one-stage phase II design was used. The study was designed
with 90% power at a 0.05 level of significance to differentiate
between a complete response (CR) rate of 10% and 30%.
Thirty-three patients were to be accrued, and if fewer than six
patients experienced a CR, it would be concluded that the
treatment regimen had insufficient activity to merit further
investigation. Secondary goals included determining overall
and progression-free survival, overall response rate (partial
CR rate), and toxicity. Kaplan-Meier curves were used to
describe overall and progression-free survival.19 Survival
time was defined as the time from registration until death or
last known follow-up. Progression-free survival was defined
as the time from registration until disease progression, death,
or last known follow-up. The frequency of toxicity was to be
tabulated by the most severe occurrence.
Patient registration and data collection were managed
by the CALGB Statistical Center. Data quality was ensured
by careful review of data by CALGB Statistical Center staff
and by the study chairperson. Statistical analyses were per-
formed by CALGB statisticians. As part of the quality assur-
ance program of the CALGB, members of the Data Audit
Committee visit all participating institutions at least once
every 3 years to review source documents. The auditors
verify compliance with federal regulations and protocol re-
quirements, including those pertaining to eligibility, treat-
ment, adverse events, tumor response, and outcome in a
sample of protocols at each institution. Such on-site review of
medical records was performed for a subgroup of 10 (27.8%)
of the 36 patients under this study.
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RESULTS
Thirty-six patients were entered onto this phase II trial
between November 2000 and April 2002 (Table 1). The
median age was 65 years (range 41–81) and 69% were men.
Fourteen of the patients were 70 years or older (39%). The
performance status was 0 in 8%, 1 in 83%, and 2 in 8%.
Thirty-four percent of the patients had experienced weight
loss of 5% or more at the time of entry onto the trial. All
patients had measurable disease.
The reasons for removal from study treatment are listed
in Table 2. Seventeen patients developed progressive disease
during treatment, 2 died, and 11 were removed from protocol
therapy because of an adverse event (7) or withdrawal of
consent for treatment (4). The seven adverse events included
grade 3 neuropathy in five (two also had grade 3 dyspnea),
grade 4 diarrhea in one, and multiple grade 2 toxicities,
including fatigue, in one patient.
The median number of chemotherapy cycles completed
was 2 (16 weeks). Eleven (31%) completed one cycle, 16
(46%) completed two cycles, 5 (14%) completed three cycles,
and 3 (9%) completed all four planned cycles (1 patient
without progression and 2 patients with progression). One
patient did not receive protocol therapy. Twenty-seven pa-
tients (77%) required a dose modification or delay in therapy.
Of these, 9 patients required one, 10 required two, and 6
required three or more dose modifications or delays. In all,
there were 67 instances of dose delays or modifications,
occurring during week 1 in 8, week 2 in 8, week 3 in 16, week
4 in 13, week 5 in 9, and week 6 in 13 patients.
The rates of grade 3 or worse toxicities of dose-dense
paclitaxel are listed in Table 3. The primary hematologic
toxicity was neutropenia with 22% of patients experiencing
grade 3/4 neutropenia. Only 6% of patients experienced
febrile neutropenia. The rates of grade 3/4 anemia and throm-
bocytopenia were less than 10%. The principal nonhemato-
logic toxicities consisted of neuropathy (37%), fatigue (20%),
dyspnea (17%) and dehydration (11%). The neuropathy was
mainly sensory in nature (26%), although motor neuropathy
was reported in 11%. There were two treatment-related
deaths, both from pneumonitis.
Of the 36 patients entered, response data were available
for 31 (86%) (Table 4). The confirmed response rate was 33%
(95% confidence interval [CI]: 19–51; 3% CR and 30%
partial response) whereas 42% had stable disease. Four pa-
tients (11%) experienced early progression. The median sur-
vival time and median progression-free survival was 9.2
months (95% CI, 6.7–14.8) and 3.7 months (95% CI, 3.3–
5.8), respectively (Table 4 and Figure 1). The 1-year survival
rate was 36% (95% CI, 23–56%) and the 1-year progression-
free survival was 17% (95% CI, 8–35%; Figure 1).
TABLE 1. Patient Characteristics
Gender
Male 25 (69)
Female 11 (31)
Age (yr)
40–49 5 (14)
50–59 9 (25)
60–69 8 (22)
70–79 12 (33)
80 2 (6)
Median age (range) 65 (41–81)
Performance status
0 3 (8)
1 30 (83)
2 3 (8)
Weight loss
Unknown 5 (14)
5% 19 (53)
5–10% 6 (17)
10% 6 (17)
Values given are n (%) values, unless indicated otherwise.
TABLE 2. Reason for Removal from Study Treatment
(n  36)
Completed all treatment without progression 1 (3)
Progressive disease 17 (47)
Death 2 (6)
Adverse event 7 (19)
Withdrew consent for treatment 4 (11)
Othera 5 (14)
Values given are n (%) values.
a One with missing data, one placed on other therapy, one did not start protocol
therapy because of myelodysplasia, and two unknown.
TABLE 3. Toxicity of Weekly Dose-Dense Paclitaxel in
ES-SCLC (n  35)a
% of Patients
Grade 3 Grade 4
Hematologic
Neutropenia 11 11
Leukopenia 9 9
Anemia 9 0
Thrombocytopenia 3 0
Febrile neutropenia 3 3
Nonhematologic
Neuropathy
Sensory 26 0
Motor 11 0
Nausea 6 0
Vomiting 6 0
Diarrhea 3 3
Dehydration 11 0
Fatigue 20 0
Hyperglycemia 6 0
Dyspnea 14 3
Pneumonitis 6 0b
Dermatitis 3 0
Thrombosis/embolism 6 0
Infection without neutropenia 3 0
a There was no toxicity data for one patient.
b There were two treatment-related deaths (grade 5), both from pneumonitis.
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DISCUSSION
This study was undertaken based on the promising
results in a number of phase II studies of dose-dense pacli-
taxel in both NSCLC and other tumors.13–17 In particular, the
CALGB phase II study in patients with advanced NSCLC by
Akerley et al. resulted in an overall response rate of 42% and
median survival of 12.3 months.17 Also, paclitaxel has been a
component of several combination regimens with demon-
strated activity in the second-line treatment of SCLC.20–22 As
has been subsequently demonstrated, however, paclitaxel has
not added to the efficacy of cisplatin/etoposide in two phase
III trials.23,24 CALGB has also studied weekly paclitaxel
compared with the standard every 3-week schedule in pa-
tients with metastatic breast cancer and found the weekly
schedule more efficacious.25
The results of the present study demonstrated response
rates that were not better compared with the more-conven-
tional every 3-week schedule of paclitaxel. The response
rates and median survival were nearly identical to those of the
North Central Cancer Treatment Group trial of paclitaxel 250
mg/m2 with G-CSF given every 3 weeks. In this trial, the
response rate was 53% and median survival was 9.1 month.9
Likewise, the response rate was 34% and median survival 9.9
months in the ECOG trial.10 Fortunately, in our study, sur-
vival was not different from that demonstrated in large phase
III trials in the Cooperative Group setting. In the CALGB
trial of etoposide/cisplatin with or without paclitaxel, median
survival was 9.9 months in the standard therapy arm, 1-year
survival was 37%, and 1-year progression-free survival was
9%.23 In the current trial median progression-free survival
was 3.7 months but 1-year progression-free survival was
17%. The reason for similar survival despite lower overall
response rate is unclear but it is more likely to be the
reflection of the effects of salvage therapy given after disease
progression. CALGB did not systematically collect details of
second-line therapy, but at least 15 patients received subse-
quent systemic chemotherapy and two received radiation
therapy after being removed from dose-dense paclitaxel (data
not shown). As expected, the most common second-line
regimen was etoposide with either cisplatin or carboplatin.
With weekly paclitaxel, myelosuppression was less
severe compared with a standard regimen of cisplatin and
etoposide. In the phase III trial, cisplatin/etoposide resulted in
grade 3 and 4 neutropenia in 66%, anemia in 17%, and
thrombocytopenia in 14%. Nevertheless, nonhematologic
toxicity seemed to be more frequent with weekly paclitaxel,
particularly peripheral neuropathy, fatigue, and dyspnea.
Also, only three patients completed all planned therapy, and
withdrawal for adverse events or patient preference was
common. This would likely make this an impractical sched-
ule for considering adding additional cytotoxic agents. Nev-
ertheless, it is difficult to directly compare the weekly pacli-
taxel regimen with more standard combination chemotherapy
because one cycle of the current regimen was a full 8 weeks
and a standard cisplatin/etoposide regimen is repeated every
3 weeks. In the phase III trial of cisplatin/etoposide 
paclitaxel, the median number of cycles delivered was 6. This
would constitute 18 weeks of chemotherapy, quite compara-
ble to two 8-week cycles of the weekly paclitaxel regimen (16
weeks).
FIGURE 1. Median overall survival (A) and median pro-
gression-free survival (B). The median progression-free sur-
vival was 3.7 months, median survival was 9.2 months. The
1-year progression-free survival was 17% and the 1-year
overall survival rate was 36%.
TABLE 4. Overall Response and Survival Rates (n  36)
Response (n  36)
Complete 1 (3)
Partial 11 (30)
Stable 15 (42)
PD 4 (11)
Unassessablea 5 (14)
Survival (n  36)
Median overall (95% CI), mo 9.2 (6.7–14.8)
1-yr overall (95% CI), % 36 (23–56)
Progression-free survival (n  36)
Median progression-free (95% CI), mo 3.7 (3.3–5.8)
1-yr progression-free (95% CI), % 17 (8–35)
CI, confidence interval.
PD, progressive disease.
Values given are n (%) values, unless indicated otherwise.
a Two patients died while receiving treatment, but before their initial disease
reassessment, two additional patients withdrew from study participation before disease
reassessment, and one patient had no response data available.
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In conclusion, for patients with ES-SCLC, dose-dense
weekly paclitaxel was associated with fairly mild hemato-
logic toxicity. Nevertheless, nonhematologic toxicities, in-
cluding neuropathy, fatigue, and dyspnea, required frequent
dose delays and reductions. The overall response rate (33%)
and CR rate (3%) are disappointing and much lower than
those seen with standard platinum/etoposide. Paclitaxel in
this dose and schedule should not be used as front-line
therapy for patients with ES-SCLC.
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